629 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms
8-K
EX-10.2
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
in respect to such Claim or litigation, and such settlement shall not include any admission as to fault on the part of the Indemnified Party. Following
8-K
EX-10.1
i1hth7p6g7c3a83i8ps9
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-2.1
691mhi4exie iqxjr
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-99.1
mm3scb5m
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
8-K
EX-10.1
39blgs8f4
25 Jan 24
Entry into a Material Definitive Agreement
8:34am
8-K
EX-1.1
89ieqwk v7ba1k6ypa3
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
8-K
EX-99.1
6h29i4310ke2wurb7pg
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
424B5
a80i6k uf
9 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
vx399w0
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
8-K
EX-99.1
3wy7pa
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm